Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel Derivatives of Nucleoside, Diaryl Ether and Benzoquinone Isolated from the Marine-Derived Fungus <i>Aspergillus</i> sp. RCDB-W7.

ACS omega·2026
Same author

Structure-Based Design of a Highly Potent Dual-Competitive FTO Inhibitor for Targeted m<sup>6</sup>A Demethylase Inhibition in AML.

Journal of medicinal chemistry·2025
Same author

Mitochondrial ClpX Inhibition Induces Ferroptosis and Blocks Pancreatic Cancer Cell Proliferation.

Chembiochem : a European journal of chemical biology·2025
Same author

Applying natural product repurposing strategy to identify baicalein as novel caseinolytic protease P inhibitor and its application in the treatment of rice bacterial diseases.

Pesticide biochemistry and physiology·2025
Same author

Identification of RAPGEF3 as the therapeutic vulnerability of basal-subtype lung squamous cell carcinoma.

Oncogene·2025
Same author

Development of Orally Bioavailable FTO Inhibitors with Potent Antileukemia Efficacy.

Journal of medicinal chemistry·2025

Related Experiment Video

Updated: Mar 12, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K

The development of small-molecule modulators for ClpP protease activity.

Fei Ye1, Jiahui Li2, Cai-Guang Yang2

  • 1College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, China.

Molecular Biosystems
|November 11, 2016
PubMed
Summary

New antibacterial drugs targeting the ClpP protease offer novel strategies against resistant pathogens. Modulating ClpP activity, through activation or inhibition, presents a dual mechanism for developing new antibiotics and antivirulence therapies.

More Related Videos

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

11.5K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.9K

Related Experiment Videos

Last Updated: Mar 12, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

11.5K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.9K

Area of Science:

  • Microbiology
  • Drug Discovery
  • Molecular Biology

Background:

  • Antibiotic resistance necessitates novel antibacterial agents with unique mechanisms of action.
  • The ClpP protease is crucial for bacterial survival and virulence, making it a promising therapeutic target.
  • Small molecules can modulate ClpP activity through overactivation or inhibition, offering dual therapeutic potential.

Purpose of the Study:

  • To review recent advancements in small molecules targeting the ClpP protease.
  • To explore the dual mechanism of ClpP modulation for antibacterial and antivirulence applications.
  • To highlight novel strategies against antibiotic-resistant bacteria and dormant infections.

Main Methods:

  • Review of scientific literature on ClpP protease modulators.
  • Analysis of acyldepsipeptides (ADEPs) and non-ADEP compounds as ClpP activators.
  • Examination of ClpP inhibitors targeting virulence factors.

Main Results:

  • Acyldepsipeptides (ADEPs) activate ClpP, leading to bacterial cell death, particularly effective against biofilm infections.
  • Non-ADEP compounds also activate ClpP, indicating a general principle for targeting dormant bacteria.
  • ClpP inhibitors are being developed to reduce bacterial virulence by targeting extracellular factors.
  • Mycobacterium tuberculosis exhibits unique ClpP inhibition by ADEPs, contrasting with general activation.

Conclusions:

  • Targeting ClpP protease activity represents a promising dual strategy for developing new antibiotics and antivirulence agents.
  • Modulating ClpP offers a novel approach to combat antibiotic resistance and treat persistent infections.
  • Further research into ClpP small-molecule modulators could yield significant therapeutic breakthroughs.